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Objective To assess the activities of levoﬂoxacin and the comparator agents ery-
thromycin, clarithromycin, azithromycin and doxycycline against atypical respiratory
pathogens.
Methods One hundred and forty-six Legionella pneumophila, 41 Mycoplasma pneumoniae
and nine Chlamydia pneumoniae isolates were procured from various culture collections in
North America and Europe and tested for susceptibility to the above agents by broth
microdilution. The isolates came primarily from clinical sources and were collected from
patients between 1995 and 1999.
Results Against L. pneumophila, levoﬂoxacin was the most active agent, with anMIC90 of
0.03mg/L, twofold more active than clarithromycin (0.06mg/L), 16-fold more active
than erythromycin and azithromycin (0.5mg/L) and 64-fold more active than doxycy-
cline. Against M. pneumoniae, azithromycin (MIC90 0.0005mg/L) was the most active
agent. However, two isolates ofM. pneumoniae, one from the USA and one from Finland,
were macrolide resistant (MIC 4mg/L), but levoﬂoxacin susceptible (MIC 0.25mg/L).
The geographic origin of L. pneumophila and M. pneumoniae did not affect the MIC range
for any antimicrobial agent tested. Against C. pneumoniae, clarithromycin was the most
active agent, with an MIC range of 0.008–0.03mg/L.
Conclusions Levoﬂoxacin had comparable activity to the other agents tested against the
atypical respiratory pathogens, conﬁrming its potential as an alternative for empirical
therapy of community-acquired pneumonia.
Keywords Legionella pneumophila, Mycoplasma pneumoniae, Chlamydia pneumoniae,
atypical pathogens, levoﬂoxacin
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INTRODUCTION
It is estimated that there are three to four million
cases of community-acquired pneumonia (CAP) in
the United States each year, resulting in 500 000
hospitalizations [1]. Streptococcus pneumoniae,
Haemophilus inﬂuenzae and Moraxella catarrhalis
are common etiologic agents; however, the atypi-
cal respiratory pathogens Legionella pneumophila,
Mycoplasma pneumoniae and Chlamydia pneumoniae
have also recently been shown to be important
etiologic factors in CAP [2,3]. In many cases, initial
therapy for CAP is empirical, and in 30–50% of
cases the causative organism is never established
[4]. Diagnosis of atypical pathogens is further
complicated by a relative absence of routine diag-
nostic testing, making it difﬁcult to estimate their
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true prevalence in CAP. Oral b-lactam antibiotics
are becoming less attractive as therapy because of
increasing resistance in S. pneumoniae; also, they do
not provide coverage against Legionella and Chla-
mydia (intracellular pathogens) due to poor intra-
cellular penetration, andM. pneumoniae, because it
lacks a cell wall. The spectrum of activity of
macrolides includes both typical and atypical
respiratory pathogens; however, a recent TRUST
surveillance study undertaken during the 1998–
1999 respiratory season in the USA [5] found
azithromycin (22.7%) and clarithromycin (23.2%)
to have the second highest resistance rates in S.
pneumoniae after trimethoprim–sulfamethoxazole
(27.3%). Studies in Europe [6] have shown similar
levels of macrolide resistance in this species, with
an aggregate 20.8% recorded in 1997–98, although
regional variations do occur. The newer ﬂuoroqui-
nolones have attracted increasing attention as
agents for empirical therapy of respiratory tract
infections because of their potent activity against
both typical and atypical pathogens. Levoﬂoxacin
is highly active against S. pneumoniae, including
penicillin-resistant isolates, and against H. inﬂuen-
zae and M. catarrhalis, including b-lactamase-pro-
ducing isolates [7]. Reports have shown that
levoﬂoxacin and other ﬂuoroquinolones have
activity against L. pneumophila, M. pneumoniae
and C. pneumoniae as well [8–14]. The objective
of the current study was to determine the anti-
microbial activity of levoﬂoxacin, comparator
macrolides and doxycycline against isolates of
L. pneumophila, M. pneumoniae and C. pneumoniae
from collections in North America and Europe.
MATERIALS AND METHODS
The 146 isolates of L. pneumophila were derived
from culture collections in the following countries:
USA (86), UK (14), France (10), The Netherlands
(10), Finland (10), Germany (9) and Denmark (7).
The 41 isolates of M. pneumoniae were derived
from collections in the USA (28), Denmark (5),
Spain (3), Finland (3), and Canada (2). The nine
isolates of C. pneumoniae included in the study
were derived from collections in the USA (6),
Finland (2) and the UK (1). Most of the isolates
were derived from clinical sources and were col-
lected from patients between 1995 and 1999.
All isolates were maintained at 80 8C until the
time of MIC testing. L. pneumophila isolates were
propagated on buffered charcoal yeast extract
(BCYE) agar plates (Hardy Diagnostics, Santa
Maria, CA, USA). M. pneumoniae isolates were
grown in SP-4 with glucose broth (Remel, Lenexa,
KS, USA) prior to testing. C. pneumoniae isolates
were propagated in HEp-2 cells (BioWhittaker,
Walkersville, MD, USA) [15].
Levoﬂoxacin was supplied by Ortho-McNeil
Pharmaceutical (Raritan, NJ, USA), azithromycin
was provided by Pﬁzer (Groton, CT, USA), clari-
thromycin was provided by Abbott (Abbott Park,
IL, USA) and erythromycin and doxycycline were
purchased from the Sigma Chemical Company (St
Louis, MO, USA).
Legionella pneumophila
MIC testingwas conducted by brothmicrodilution
according to NCCLS guidelines [16] for aerobic
bacteria (M7-A5, 2000) using 96-well microtiter
plates containing the test antimicrobial concentra-
tions. The bacterial inoculum was prepared from
an overnight culture grown on BCYE agar at 35 8C
in a humidiﬁed chamber. A suspension of organ-
isms equivalent to a 0.5 McFarland standard was
prepared in buffered yeast extract (BYE) broth
and was diluted to give a concentration of
0.5–1 106CFU/mL in a ﬁnal volume of 100 mL.
Plates were incubated at 35 8C in air, and the MIC
was read as the ﬁrst well showing no visible
growth at 48 h. Control strains were L. pneumophila
ATCC 33152 and Staphylococcus aureus ATCC
29213.
Mycoplasma pneumoniae
MIC testing was based on a broth microdilution
method described by Waites et al. [17]. Brieﬂy, the
method uses a chromogenic substrate, SP-4 with
glucose (SP-4G; Remel) as an indicator of growth.
Fermentation of glucose, as a result of growth,
produces an acid byproduct which changes the
medium from red to yellow. Serial 10-fold dilu-
tions of each isolate were prepared in tubes con-
taining SP-4G to determine the number of color-
changing units (CCU). The CCU method is a
dilution method for determining the number of
mycoplasmas in a broth culture, the endpoint
being the reciprocal of the highest dilution in
which growth was present as evidenced by a color
change in the medium. These titers were used to
adjust the inoculum used in the MIC test to
approximately 104 CCU/mL. Antibiotics were
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serially diluted in antibiotic-free SP-4G. The inocu-
lated plates were incubated aerobically at 35 8C
and examined daily until a color change was
detected in the drug-free (growth control) wells.
The MIC endpoint was determined as the lowest
concentration of antimicrobial agent at which the
metabolism of the organism was inhibited, as
evidenced by a color change, 24 h after the growth
control changed color. Any isolate that was resis-
tant to an agent was re-tested on another day to
ensure reproducibility of the results. Control
strains were M. pneumoniae ATCC 15331 and S.
aureus ATCC 29213.
Chlamydia pneumoniae
Susceptibility testing of C. pneumoniae was con-
ducted with HEp-2 cells, using a slight modiﬁca-
tion of the methods described by Gieffers et al. [18]
and Hammerschlag et al. [19]. The HEp-2 cells
were grown in 24-well microtiter plates and inocu-
lated with 100 mL of the test organism diluted in
Eagles’ Minimal Essential Medium (EMEM) to
contain between 103 and 104 inclusion-forming
units/mL. Prior titration studies established this
optimum concentration. The microtiter plates
were centrifuged for 1 h at 1500 g and then incu-
bated for 1 h at 35 8C. The inoculum-containing
wells of each plate were then aspirated and the
cells washed with 200–300 mL of Hanks Balanced
Salt Solution. The Hanks medium was then aspi-
rated and the cell monolayer was overlayed with
500 mL of chlamydia overlaymedium (COM)with-
out antimicrobial agents. Serial dilutions were
made by adding 500 mL of the antimicrobial agent
to be tested to the ﬁrst well and serially diluting
500 mL through the rest of the wells. One well
without antibiotic was used as the growth control.
The plates were incubated at 35 8C for 72 h in 5%
CO2. COM was aspirated, and the monolayer was
ﬁxed and stained with a Chlamydia-speciﬁc ﬂuor-
escent monoclonal antibody (Meriﬂuor Chlamy-
dia; Meridian Diagnostics, Cincinnati, OH, USA).
The MIC was determined as the lowest concentra-
tion at which no inclusions were observed. Control
strains were C. pneumoniae ATCC VR-1360 and S.
aureus ATCC 29213.
RESULTS
The results in Table 1 show the activity of levoﬂox-
acin and comparator agents against L. pneumophila T
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isolates from the USA and Europe. Levoﬂoxacin
was the most active agent (MIC90 0.03mg/L),
closely followed by clarithromycin (MIC90
0.06mg/L). Azithromycin and erythromycin were
the least active agents (MIC90 0.5mg/L). Geo-
graphic origin of the isolates had no signiﬁcant
impact on susceptibility to levoﬂoxacin, the com-
parator macrolides, or doxycycline, as there was
little variation in the MIC ranges for each antimi-
crobial agent against the isolates from each coun-
try. The isolates that were most susceptible to
levoﬂoxacin (MIC 0.015mg/L) originated in
Germany and The Netherlands. Analysis of MIC
distributions for all ﬁve agents against all 146
isolates tested showed that levoﬂoxacin was the
most active agent, with a modal MIC of 0.015mg/
L, and this activity was maintained within a nar-
row range from 0.008 to 0.03mg/L. The modal
MICs for clarithromycin, azithromycin and ery-
thromycin were 0.03, 0.12 and 0.25mg/L, respec-
tively, withMICs that spannedwide ranges: 0.008–
0.12mg/L for clarithromycin, 0.03–0.5mg/L for
azithromycin, and 0.06–0.5mg/L for erythromy-
cin. Doxycycline MICs ranged from 1 to 4mg/L,
the highest of all agents tested.
The results in Table 2 show the activity of levo-
ﬂoxacin and comparator agents against 41 isolates
of M. pneumoniae from the USA, Canada, Den-
mark, Finland, and Spain. Azithromycin demon-
strated remarkable potency (MIC90 0.0005mg/
L) and was eightfold more active than clarithro-
mycin (MIC90 0.004mg/L) and 30-foldmore active
than erythromycin (MIC90 0.015mg/L). Doxycy-
cline and levoﬂoxacin were the least active agents,
with MIC90s of 0.5 and 1mg/L, respectively. Inter-
estingly, in the case of levoﬂoxacin, all isolates
were inhibited at concentrations of 1mg/L. This
is in contrast to the macrolides, where two isolates
were not inhibited at concentrations of4mg/L of
azithromycin, clarithromycin and erythromycin.
The two macrolide-resistant isolates, which origi-
nated in Finland and the USA, were inhibited by
levoﬂoxacin at a concentration of 0.25mg/L, and
by doxycycline at 0.5mg/L (Table 3).
Table 2 Antimicrobial susceptibility of 41 isolates of M.
pneumoniae
MIC (mg/L)
Antimicrobial Range MIC50 MIC90 Mode
Levofloxacin 0.25–1 0.25 1 0.25
Erythromycin 0.002 to 8 0.008 0.015 0.008
Clarithromycin 0.001 to 8 0.002 0.004 0.002
Azithromycin 0.0005 to 8 0.0005 0.0005 0.0005
Doxycycline 0.12–0.5 0.25 0.5 0.25
Table 3 Antimicrobial susceptibility of two macrolide-resistant isolates of M. pneumoniae
MIC (mg/L)
Isolate no. Country of origin Levofloxacin Erythromycin Clarithromycin Azithromycin Doxycycline
1 USA 0.25 >8 >8 4 0.25
2 Finland 0.25 >8 >8 >8 0.5
Table 4 Antimicrobial susceptibility of nine C. pneumoniae isolates
MIC (mg/L)
Isolate no. Country of origin Levofloxacin Clarithromycin Azithromycin Doxycycline
1 Finland 0.25 0.03 0.06 0.25
2 Finland 1 0.008 0.12 0.12
3 UK 0.5 0.015 0.06 0.25
4 USA 0.25 0.03 0.12 0.12
5 USA 0.25 0.015 0.12 0.06
6 USA 0.5 0.015 0.06 0.06
7 USA 0.5 0.008 0.06 0.12
8 USA 0.5 0.015 0.06 0.06
9 USA 0.25 0.008 0.06 0.12
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Levoﬂoxacin and comparator agents were also
tested against nine isolates of C. pneumoniae, of
which seven originated in the USA and two in
Finland. The MICs for all antimicrobial agents
tested against all nine isolates are shown in Table 4.
The most active agent was clarithromycin, with
MICs of 0.008mg/L for three isolates, 0.015mg/
L for four isolates and 0.03mg/L for two isolates.
Azithromycin was the next most active agent, with
MICs ranging from 0.06mg/L (six isolates) to
0.12mg/L (three isolates). DoxycyclineMICs were
0.06mg/L (three isolates), 0.12mg/L (four iso-
lates) and 0.25mg/L (two isolates). Levoﬂoxacin
was also active againstC. pneumoniae, withMICs of
0.25mg/L (four isolates), 0.5mg/L (four isolates)
and 1mg/L (one isolate). The fact that all agents
were tested against C. pneumoniae cultivated in a
HEp-2 cell line also conﬁrms their ability to pene-
trate mammalian cells and retain antibacterial
efﬁcacy.
DISCUSSION
L. pneumophila is a facultative intracellular patho-
gen that has the ability to multiply within the
phagosome of alveolar macrophages and blood
monocytes [20]. As a consequence of its intracel-
lular location, L. pneumophila is capable of evading
the inhibitory effects of agents such as b-lactams,
which are unable to penetrate host cell mem-
branes. Macrolides have the ability to penetrate
mammalian cells, so erythromycin is ﬁrst-line
therapy for L. pneumophila infections [8,9,11].
Unfortunately, there are a number of issues
associated with the use of erythromycin, includ-
ing the large volume required for intravenous
infusion, ototoxicity and gastrointestinal intoler-
ance [21]; the recent introduction of parenteral
azithromycin has partially addressed these issues.
The ﬂuoroquinolones have also shown potent
efﬁcacy against L. pneumophila in broth micro-
dilution studies [8,9,22] and against intracellular
L. pneumophila cultivated in mammalian cell lines
[8–10].
In the present study, the ﬂuoroquinolone levo-
ﬂoxacin demonstrated potent activity against 146
isolates of L. pneumophila from the USA and Eur-
ope. Levoﬂoxacin was 20-fold more active than
erythromycin, based onMIC90 values of 0.03mg/L
and 0.5mg/L, respectively. Levoﬂoxacin at 1mg/
L has been shown to have bactericidal activity
against intracellular organisms grown in guinea
pig alveolar macrophages by reducing the viable
counts of two isolates by 2–3 log10 CFU/mL,
and was signiﬁcantly more effective than erythro-
mycin in the same model [9]. Furthermore,
the ﬂuoroquinolones have also been shown to
have a signiﬁcant postantibiotic effect against
L. pneumophila [23,24]. Uncontrolled clinical trials
have shown that the newer ﬂuoroquinolones,
including levoﬂoxacin, were effective in treating
both community-acquired and nosocomial infec-
tions [25,26]. As a consequence, agents such as
levoﬂoxacin may prove to be as efﬁcacious as
the macrolides for the therapy of L. pneumophila
infections, with the advantage of fewer side-
effects.
The results of this study also demonstrated
the potent efﬁcacy of the macrolides against
M. pneumoniae, conﬁrming the observations of
other investigators [12,27]. However, two iso-
lates of M. pneumoniae tested in this study had
reduced susceptibility to erythromycin, clari-
thromycin and azithromycin (MICs4mg/L).
There are numerous reports of macrolide-resistant
isolates recovered from patients following therapy
with macrolides [28–31]. In addition, erythro-
mycin-resistant isolates can also be generated
in the laboratory [32]. Such isolates have been
shown to have point mutations in their 23S
rRNA genes, resulting in ribosomes having redu-
ced afﬁnity for the macrolide [33]. Although
levoﬂoxacin was less active than the macrolides
based on MIC90 (0.0005mg/L for azithromycin
compared with 1mg/L for levoﬂoxacin), it did
retain activity against the two macrolide-resistant
isolates (MICs of 0.25mg/L for both isolates),
indicating that it may have potential in the
therapy of infections caused by macrolide-
resistant isolates.
Levoﬂoxacin was also active against the obligate
intracellular pathogen C. pneumoniae, with MICs
ranging from 0.25 to 1mg/L. These results were in
agreement with results generated by other inves-
tigators using Hep-2 cell lines for organism culti-
vation and susceptibility testing [13,14,34]. The
fact that levoﬂoxacin is active against C. pneu-
moniae in this model indicates that this agent
has the ability to penetrate host cells and retain
antimicrobial activity. No standards have been
adopted for antimicrobial susceptibility testing
of C. pneumoniae, although the C. pneumoniae
workshop group on Detection, Culture, Serology
and Antimicrobial Susceptibility Testing has made
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 214–221
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a strong recommendation for the adoption of
standardized procedures [35]. The choice of cell
line used for susceptibility testing can affect the
susceptibility test results. For example, Roblin
et al. [15] have shown that McCoy cells used
by various investigators [36] are 10- and 100-fold
less prone to infection with C. pneumoniae than
HEp-2 cells, which may result in lower MIC
endpoints.
In conclusion, MIC studies have shown that the
ﬂuoroquinolone levoﬂoxacin is active against both
L. pneumophila and M. pneumoniae. Furthermore,
evaluating the efﬁcacy of levoﬂoxacin against C.
pneumoniae in an intracellular model conﬁrms the
ability of this agent to penetrate mammalian cells
and retain intracellular antibacterial activity. Levo-
ﬂoxacin is rapidly bactericidal and may be admi-
nistered once a day for mild-to-severe infections
[37–39]. There are also clinical data to demonstrate
the efﬁcacy of levoﬂoxacin in the treatment of
adults with CAP, achieving greater than 98% suc-
cess in patients infected with atypical pathogens,
including L. pneumophila, M. pneumoniae and C.
pneumoniae [25,40]. The current study showed that
geographic origin of the atypical pathogen (North
America or Europe) did not affect its susceptibility
to levoﬂoxacin. Collectively, these results conﬁrm
the potential for levoﬂoxacin as therapy for CAP
caused by atypical respiratory pathogens.
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